Among them, an MTH1 inhibitor TH588 excelled other top ranked candidate targeted agents and exhibited a strong synergistic anti-glioma effect with BKM120, thus offering a potential combination therapy for further evaluation in GBM models. This evidence concerns the gene NUDT1 and central nervous system cancer.